Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib in Tumors With FGFR Amplifications (MATCH Subprotocol K1)
NCT06308822Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erdafitinib in lymphoma, Solid neoplasm, multiple myeloma (MM), sponsored by National Cancer Institute. Started Aug 2018; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
lymphomaSolid neoplasmmultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06308822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308822.